Brief Introduction

Founded in 2009, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Zelgen) is located in the Kunshan National New and High-Tech District in Jiangsu Province, China. Zelgen is a joint venture established by Chinese and American pharmaceutical experts, forming the company from four subsidiaries, US Gensun Biopharma Inc., Shanghai Zelgen Pharma-Tech Co. Ltd., Suzhou Zelgen Biosciences Co. Ltd., and Zelgen Holding Ltd. Zelgen specializes in the research and development (R&D), production, and distribution of innovative medicines. Zelgen is one of the leading pharmaceutical companies in China focusing on the areas of oncology, hematology, immuno-inflamation and gastroenterology. The company's market strategy emphasizes China, while expanding business opportunities internationally. Zelgen's mission is to develop innovative drugs for unmet therapeutic markets that are safe, efficatious, affordable, and for which we have intellectual property ownership.

The maintenance of a robust, proprietary pipeline is crucial to Zelgen's business. Zelgen has established two cutting-edge technology platforms, the R&D platform and commercial production platform, for both small molecule drugs and recombinant protein drugs including novel bi/tri-specific antibodies. This has enabled Zelgen to build a strong pipeline covering treatment areas including liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, alopecia areata, ankylosing spondylitis, atopic dermatitis, hepatobiliary diseases et al. Zelgen is also working together with several other pharmaceutical companies to co-develop combination treatments of TKI and check-point inhibitors.

Company Overview

Full name Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Abbreviations Zelgen
Code 688266
Founded 2009.03.18
Listing 2020.01.23
Domicile Kunshan, Jiangsu Province
STAR Theme Biomedicine
CSRCSector Manufacturing
Has weighted voting rights structure? No



  2018 2017 2016
Earnings Per Share - - -
R&D expenditure as a % of operating revenue - - -
Operating Revenue 1.31 - 0.20
Net Income -441.88 -146.47 -128.27

Income Statement (Unit: RMB mn)

  2018 2017 2016
Operating Revenue 1.31 - 0.20
Operating Costs 0.89 - 0.16
Operating Income -442.65 -146.47 -133.63
Pretax Income -442.66 -146.47 -128.27
Income Tax -0.78 - -
Net Income -441.88 -146.47 -128.27

Balance Sheet(Unit: RMB mn)

  2018 2017 2016
Current Assets-Total 229.67 71.64 80.92
Non-current Assets-Total 225.21 75.99 56.28
Total Assets 454.88 147.63 137.20
Current Liabilities-Total 77.56 69.38 12.02
Non-current Liabilities-Total 95.69 5.23 15.74
Total Liabilities 173.24 74.61 27.76
Stockholder's Equity
Share Capital 1,023.82 429.67 319.61
Retained Profits -797.51 -356.64 -210.18
Minority Interests 55.33 - -
Total Owners' Equity 281.64 73.02 109.44

Cash Flow Statement (Unit: RMB mn)

  2018 2017 2016
Net Cash Flows-Operating -112.44 -108.25 -56.72
Net Cash Flows-Investing -53.11 -8.83 -57.43
Net Cash Flows-Financing 285.37 110.06 124.79

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
ZELIN SHENG 49.64 20.68%
宁波泽奥股权投资管理合伙企业(有限合伙) 16.50 6.88%
HUIPING LU 12.57 5.24%
石河子康润股权投资有限合伙企业 10.03 4.18%
昆山市工业技术研究院小核酸生物技术研究所有限责任公司 10.03 4.18%
苏州博澳股权投资合伙企业(有限合伙) 9.22 3.84%
宁波梅山保税港区璞石新兴股权投资合伙企业(有限合伙) 6.12 2.55%
23 Jan 2020

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.